Scott Clulow, DO
Family Medicine · Bradenton, FLNPI 1174518310
Payments from drug & device makers
Across 333 payments — averaging $18.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$908
- AbbVie$728
- AstraZeneca$677
- Lilly USA, LLC$649
- GSK$484
- Amgen$416
- plus $2K from 29 others
What the payments were for
- Food & beverage$6,052100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 56 | $908 |
| AbbVie(2 entities) | 37 | $728 |
| AstraZeneca | 37 | $677 |
| Lilly USA, LLC | 44 | $649 |
| GSK | 28 | $484 |
| Amgen | 25 | $416 |
| Pfizer | 19 | $336 |
| Exact Sciences | 12 | $321 |
| Bayer | 12 | $255 |
| Boston Scientific | 4 | $187 |
| Boehringer Ingelheim | 9 | $157 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $89 |
| Johnson & Johnson | 4 | $86 |
| Astellas Pharma US Inc | 5 | $74 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $64 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $64 |
| Dexcom, Inc. | 3 | $58 |
| Abbott | 3 | $56 |
| Novartis | 3 | $45 |
| Idorsia Pharmaceuticals US Inc | 2 | $36 |
| Merck | 2 | $32 |
| Vanda Pharmaceuticals Inc. | 1 | $32 |
| Antares Pharma, Inc. | 2 | $31 |
| Philips North America LLC | 2 | $31 |
| Daiichi Sankyo Inc. | 1 | $28 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| Inari Medical, Inc. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Nevro Corp. | 1 | $23 |
| Radius Health, Inc. | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $21 |
| Integra Lifesciences Corporation | 1 | $21 |
| Scilex Pharmaceuticals Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,052 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 95 | $109,396 |
| EliquisApixaban | 82 | $91,103 |
| MounjaroTirzepatide | 61 | $62,360 |
| JardianceEmpagliflozin | 61 | $52,278 |
| TrulicityDulaglutide | 48 | $50,695 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $45,735 |
| XareltoRivaroxaban | 41 | $41,603 |
| Dupixent SyringeDupilumab | 11 | $41,073 |
| RybelsusSemaglutide | 19 | $22,104 |
| FarxigaDapagliflozin Propanediol | 24 | $15,492 |
| Repatha SyringeEvolocumab | 13 | $14,770 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $14,369 |
| JanuviaSitagliptin Phosphate | 16 | $12,835 |
| MyrbetriqMirabegron | 11 | $12,638 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $10,303 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $908 | $131,500114 claims |
| Lilly USA, LLCMounjaro, Trulicity | $649 | $113,055109 claims |
| PfizerEliquis | $336 | $91,10382 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $484 | $56,03867 claims |
| Boehringer IngelheimJardiance | $157 | $52,27861 claims |
| Johnson & JohnsonXarelto | $86 | $41,60341 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $677 | $29,86137 claims |
| MerckJanuvia | $32 | $12,83516 claims |
| Astellas Pharma US IncMyrbetriq | $74 | $12,63811 claims |
| AbbVieLumigan, Synthroid, Armour Thyroid | $728 | $6,78552 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Bradenton
- Eric FolkensBradenton$5.4M
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.